Kemwell Biopharma purchases US development services firm Cirrus Pharmaceuticals
A step in the plan to build a leading global contract services company
Kemwell Biopharma, a global contract services company headquartered in Bangalore, India, has bought Cirrus Pharmaceuticals, a contract development services company based in Research Triangle Park, NC, US, for an undisclosed sum.
Established in 1997, Cirrus has expertise in the development of inhalation, parenteral, transdermal, topical and liquid dosage forms. It also offers analytical services including stability studies.
‘Cirrus will complement the existing contract services offered by Kemwell with early stage innovative product development,’ said Anurag Bagaria, Chairman and MD of Kemwell.
‘Kemwell will now provide customers with a complete solution from early development in the US to commercial manufacturing in Kemwell's EMA, FDA and PMDA approved facilities in India and Sweden.’
Ninad Deshpanday, President R&D at Kemwell added: ‘With Cirrus' development capabilities and Kemwell's manufacturing expertise, we will be able to develop products with faster time-to-clinic and significant cost savings for our customers.’
Cirrus' President Anthony Hickey said the acquisition will ‘transform Cirrus into a global player in R&D services by significantly strengthening our capabilities in inhalation R&D and increasing offerings in other areas such as oral solids dosage forms’.
